The Morning Brief Corner Office Conversation With Prashant Warier, Ankit Modi and Preetham Putha of Qure.ai
Jan 26, 2026
Prashant Warier, Co-founder and CEO of Qure.ai, leads a team using AI to transform routine X-rays into early disease detection. They discuss scaling diagnostic AI globally. Topics include TB screening wins, lung nodule risk scoring with high CT-confirmed malignancy, FDA and WHO clearances, and the path to profitability while aiming to impact a billion lives.
AI Snips
Chapters
Transcript
Episode notes
Beyond Images: Diagnostics As A Pathway
- Radiology is one part of diagnosis, and early detection across diseases improves survival and quality of life.
- Qure.ai pivots from image reading to building AI that shortens diagnostic pathways and speeds follow-up care.
Pay Upfront For Validation And Regulation
- Invest heavily in data, expert annotations, clinical validation and regulatory clearances before scaling commercial deployment.
- Expect upfront R&D and regulatory costs, then low incremental servicing costs once products are live.
Integration Creates Competitive Moat
- Few companies combine AI models, platform integration and clinical workflow coordination at global scale like Qure.ai.
- Continuous product innovation across disease workflows creates a defensible, integrated offering.